Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
10.1007/s11596-015-1456-8
- Author:
Qiu-Ling WU
1
;
Xiao-Yun LIU
;
Di-Min NIE
;
Xia-Xia ZHU
;
Jun FANG
;
Yong YOU
;
Zhao-Dong ZHONG
;
Ling-Hui XIA
;
Mei HONG
Author Information
1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China, wuqiuling@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Cord Blood Stem Cell Transplantation;
methods;
Cytokines;
metabolism;
Dendritic Cells;
metabolism;
Female;
Graft vs Host Disease;
immunology;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Immunomodulation;
Killer Cells, Natural;
metabolism;
Male;
T-Lymphocyte Subsets;
metabolism;
Transplantation, Homologous;
adverse effects;
Young Adult
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(4):477-484
- CountryChina
- Language:English
-
Abstract:
Although mesenchymal stem cells (MSCs) are increasingly used to treat graft-versus-host disease (GVHD), their immune regulatory mechanism in the process is elusive. The present study aimed to investigate the curative effect of third-party umbilical cord blood-derived human MSCs (UCB-hMSCs) on GVHD patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their immune regulatory mechanism. Twenty-four refractory GVHD patients after allo-HSCT were treated with UCB-hMSCs. Immune cells including T lymphocyte subsets, NK cells, Treg cells and dendritic cells (DCs) and cytokines including interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-α) were monitored before and after MSCs transfusion. The results showed that the symptoms of GVHD were alleviated significantly without increased relapse of primary disease and transplant-related complications after MSCs transfusion. The number of CD3(+), CD3(+)CD4(+) and CD3(+)CD8(+) cells decreased significantly, and that of NK cells remained unchanged, whereas the number of CD4(+) and CD8(+) Tregs increased and reached a peak at 4 weeks; the number of mature DCs, and the levels of TNF-α and IL-17 decreased and reached a trough at 2 weeks. It was concluded that MSCs ameliorate GVHD and spare GVL effect via immunoregulations.
